OPKO Health, Inc.: all 58 studies

Page 1 of 1. Open to participants first (6), then studies with results posted, then the rest; newest registration first within each.

• Phase 1/2 Study of OPK-88006 in Healthy and Presumed MASH ParticipantsRecruitingNCT07512427Phase 1/2
• Pharmacokinetics, Pharmacodynamics, Safety and Tolerability Evaluation of CTAP101 Extended-release Capsules in Pediatric ParticipantsRecruitingNCT07494045Phase 2
• A Study Evaluating MDX2301 in Healthy Adults and Adults at Higher Risk for Severe COVID-19.RecruitingNCT07445971Phase 1
• Dose Escalation and Dose Expansion Study of MDX2003 in Patients With Different Types of LymphomaRecruitingNCT07249905Phase 1/2
• Dose Escalation and Dose Expansion Study of MDX2004 in Participants With Advanced TumorsRecruitingNCT07110584Phase 1/2
• Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid TumorsRecruitingNCT06239194Phase 1/2
• Phase 3 Safety and Efficacy Study of CTAP101 Extended-release Capsules in Children With Secondary HyperparathyroidismTerminatedNCT05543928Phase 3Results posted
• Safety and Efficacy of Rayaldee for Treating Mild to Moderate COVID-19CompletedNCT04551911Phase 2Results posted
• Safety and Efficacy Study of MOD-4023 to Treat Children With Growth Hormone DeficiencyCompletedNCT03874013Phase 3Results posted
• Safety, Efficacy, PK and PD of CTAP101 (Calcifediol) ER Capsules for SHPT in HD Patients VDITerminatedNCT03602261Phase 2Results posted
• Repeated-dose Safety, Efficacy, Pharmacokinetic and Pharmacodynamic of CTAP101, Immediate-release Calcifediol, High-dose Cholecalciferol, and Paricalcitol Plus Low-dose Cholecalciferol in Patients With Secondary Hyperparathyroidism, Chronic Kidney Disease 3-4 and Vitamin D InsufficiencyCompletedNCT03588884Phase 4Results posted
• Effects and Safety of OPK-88003 Dose Escalation in Type 2 Diabetes SubjectsCompletedNCT03406377Phase 2Results posted
• Effects and Safety of OPK-88004 Doses in Men With Signs and Symptoms of Benign Prostatic Hyperplasia (BPH)TerminatedNCT03297398Phase 2Results posted
• Safety and Efficacy Phase 3 Study of Long-acting hGH (MOD-4023) in Growth Hormone Deficient ChildrenCompletedNCT02968004Phase 3Results posted
• Long Term Follow up Study of Long-acting hGH (MOD-4023) in Growth Hormone Deficient ChildrenCompletedNCT02500316Phase 2Results posted
• Extension Study of CTAP101-CL-3001 or CTAP101-CL-3002CompletedNCT02282813Phase 3Results posted
• A Study of LY2944876 in Healthy Japanese and Non-Japanese ParticipantsTerminatedNCT02188303Phase 1Results posted
• A Study to Compare a New Drug for Type 2 Diabetes to Placebo and to a Treatment Already Available for Type 2 DiabetesCompletedNCT02119819Phase 2Results posted
• A Phase 3, Multicenter Study To Evaluate The Efficacy And Safety Of MOD-4023 In Adults With Growth Hormone DeficiencyTerminatedNCT01909479Phase 3Results posted
• A 4-Week Safety Study of Oral ELND005 in Young Adults With Down Syndrome Without DementiaCompletedNCT01791725Phase 2Results posted
• A 36-Week Safety Extension Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's DiseaseTerminatedNCT01766336Phase 2Results posted
• Efficacy and Safety Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's DiseaseCompletedNCT01735630Phase 2Results posted
• Safety and Efficacy of CTAP101 to Treat Secondary Hyperparathyroidism in Stage 3 or 4 CKD and Vitamin D InsufficiencyCompletedNCT01704079Phase 3Results posted
• Safety and Efficacy Study of ELND005 as an Adjunctive Maintenance Treatment in Bipolar I DisorderTerminatedNCT01674010Phase 2Results posted
• Safety and Efficacy of CTAP101 to Treat Secondary Hyperparathyroidism in Stage 3 or 4 CKD and Vitamin D InsufficiencyCompletedNCT01651000Phase 3Results posted
• Safety and Efficacy Phase 2 Study of Long-acting hGH (MOD-4023) in Growth Hormone Deficient ChildrenCompletedNCT01592500Phase 2Results posted
• Safety/Efficacy Study of CTAP101 in Chronic Kidney Disease Subjects With Secondary Hyperparathyroidism (SHPT)CompletedNCT01219855Phase 2/3Results posted
• ELND005 Long-Term Follow-up Study in Subjects With Alzheimer's DiseaseCompletedNCT00934050Phase 2Results posted
• ELND005 in Patients With Mild to Moderate Alzheimer's DiseaseCompletedNCT00568776Phase 2Results posted
• Safety & Efficacy Study Evaluating the Combination of Bevasiranib & Lucentis Therapy in Wet AMDTerminatedNCT00499590Phase 3Results posted
• 4Kscore Using Serum Stored UncentrifugedCompletedNCT04130776
• Quality of Life and Visual Acuity of Visglyc Eye Drops on Dry Eye PatientsCompletedNCT04063644Not applicable
• A Clinical Study Investigating the Comparability of Somatrogon in Two Different Drug Product PresentationsCompletedNCT03810664Phase 1
• Efficacy and Safety of a Intra-articular Injection, ENKO1, in Patients With Symptomatic Knee Osteoarthritis.CompletedNCT03762408Not applicable
• Pharmacokinetics and Safety Study of CTAP101 Capsules in Japanese and Non-Japanese Healthy Subjects and Non-Japanese Healthy SubjectsCompletedNCT03660800Phase 1
• Efficacy and Tolerability of a Nutritional Supplement, Plactive Progen, in ACL ReconstructionCompletedNCT03355651Not applicable
• A Single-dose, Dose-escalation Study of a Long-acting MOD-5014 in Healthy Adult MaleCompletedNCT02919800Phase 1
• A Single-dose, Dose-escalation Study of a Long-acting MOD-6031 in Healthy Overweight or Obese SubjectsCompletedNCT02692781Phase 1
• A Study of a Long-Acting r-Factor 7a (Factor VIIa) in Adult Men With Hemophilia A or BCompletedNCT02418793Phase 1
• Pharmacokinetics and Pharmacodynamics of Long Acting Human Growth Hormone (hGH) Product (MOD-4023) in Healthy Caucasian and Japanese VolunteersCompletedNCT02418767Phase 1
• Effect of CTAP101 Capsules on Ca/iPTH in Advanced Breast/Prostate Cancer Patients Treated With Denosumab/Zoledronic AcidCompletedNCT02274623Phase 1
• Four Week, Pharmacodynamic/Pharmacokinetic, Efficacy, and Safety Study of Lunacalcipol (CTA018)WithdrawnNCT01453634Phase 2
• Effects of TT301 on Cytokine Levels Post Endotoxin ChallengeCompletedNCT01357421Phase 1
• MOD-4023 (Long-Lasting Human Growth Hormone (hGH)) Study in Growth Hormone Deficient Adults (GHDA)CompletedNCT01225666Phase 2
• MOD-4023 Study in Healthy Male VolunteersCompletedNCT01060722Phase 1
• Pharmacokinetics and Safety Pilot Study of Single-Dose Oral and Intravenous CTAP101 in Stage 3 and 4 Chronic Kidney Disease SubjectsCompletedNCT00888069Phase 1
• A Prospective, Multicenter, Open-label, Safety and Preliminary Efficacy Study of the Surgical Implantation of OPKO's Glaucoma Drainage Device (AquashuntTM) in Patients With Refractory Chronic Forms of Open Angle Glaucoma (OAG)CompletedNCT00834223Not applicable
• Comparison of I.V. CTAP201 and Doxercalciferol (Hectorol) in Subjects With Chronic Kidney Disease (CKD) and Secondary Hyperparathyroidism (SHPT)CompletedNCT00792857Phase 1
• A Trial of TT223 in Patients With Type 2 Diabetes Who Are Taking Metformin and/or ThiazolidinedioneCompletedNCT00743002Phase 2
• Safety Study of CTA018 Injection to Treat Stage 5 Chronic Kidney DiseaseCompletedNCT00742716Phase 2
• Open Label Study for the Evaluation of Tolerability of Five Dose Levels of Cand5CompletedNCT00722384Phase 1
• Safety & Efficacy Study Evaluating the Combination of Bevasiranib & Lucentis Therapy in Wet AMD (CARBON)WithdrawnNCT00557791Phase 3
• Safety and Efficacy of Topically Applied CTA018 in Plaque PsoriasisCompletedNCT00384098Phase 2
• Safety and Efficacy Study of Small Interfering RNA Molecule (Cand5) to Treat Diabetic Macular EdemaCompletedNCT00306904Phase 2
• Safety and Efficacy Study of Small Interfering Ribonucleic Acid (RNA) Molecule (Cand5) to Treat Wet Age-Related Macular DegenerationCompletedNCT00259753Phase 2
• A Study in Type 2 Diabetic Patients With Repeated Doses of E1 in Combination With G1CompletedNCT00239187Phase 1
• A Study in Type 1 Diabetic Patients With Repeated Doses of E1 in Combination With G1CompletedNCT00239148Phase 1
• Study in Non-responder Hepatitis C Genotype 1 Patients With EMZ702, Pegylated Interferon and RibavirinCompletedNCT00230854Phase 1

← OPKO Health, Inc. overview and focus areas